Form 4: Supernus Pharmaceuticals Executive Settles Performance Share Units
SEC Form 4 Filing
Frank Mottola, SVP at Supernus Pharmaceuticals, settled performance share units and had shares withheld for tax obligations on February 28, 2024.
Summary
- On February 28, 2024, Frank Mottola, SVP at Supernus Pharmaceuticals, settled 990 Performance Share Units, receiving common stock.
- The company withheld 460 shares of common stock to cover tax obligations related to the vesting of these units at a price of $27.94.
- Following these transactions, Mottola directly owns 7,779 shares of Supernus Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: This is a routine disclosure of executive stock transactions, with no inherent positive or negative implications for the company's overall performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track executive compensation and ownership changes.
Stakeholder Impact
- Shareholders can monitor insider transactions for insights into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 02/22/2022 | Reporting Person was awarded Performance Share Units |
| 05/03/2022 | Objectives were established for Performance Share Units |
| 02/28/2024 | Settlement of Performance Share Units and tax withholding. |
| 02/29/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.